---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-005145"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:21:23.461720+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma boosts ATM equity facility from $5.2M to $30.2M; $5.19M already sold

## Summary
- On July 30, 2024, CNS Pharmaceuticals increased the aggregate sales price under its ATM agreement to $25M, for a total of $30.2M including original $5.2M.
- As of July 30, 2024, the Company sold 7,206,743 shares for gross proceeds of approximately $5.19 million.
- Outstanding shares as of July 30, 2024: 10,075,017; remaining capacity implies significant potential dilution.
- Sales are conducted through A.G.P./Alliance Global Partners under an effective S-3 shelf registration.

## SEC filing metadata
- accession: 0001683168-24-005145
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824005145/0001683168-24-005145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824005145/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-005145
- JSON: https://secwatch.observer/filing/0001683168-24-005145.json
- Plain text: https://secwatch.observer/filing/0001683168-24-005145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.